How Investors Are Reacting To Mineralys Therapeutics (MLYS) Long Term Blood Pressure Data
- Mineralys Therapeutics reported that long term efficacy and safety results from its Transform-HTN open label extension study of lorundrostat in uncontrolled hypertension were presented as a late breaking session at the American Heart Association Scientific Sessions 2026 in Chicago.
- The late breaking slot for Transform-HTN highlights how lorundrostat now has extended exposure data on blood pressure and tolerability across multiple late stage trials. This speaks directly to Mineralys Therapeutics' effort to build a comprehensive evidence package around aldosterone synthase inhibition in difficult to treat hypertension and related conditions.
- We will now look at how Mineralys Therapeutics' investment narrative intersects with this long term Transform HTN data at AHA.
Mineralys Therapeutics Investment Narrative Recap
Mineralys Therapeutics is essentially a single asset story around lorundrostat. To be a shareholder, you need to believe this aldosterone synthase inhibitor can secure approval in uncontrolled and resistant hypertension and then find real world prescribing traction. The Transform HTN long term data at AHA appears to provide incremental support for that thesis rather than a step change in the near term outlook.
The most important short term catalyst remains regulatory progress on an NDA for hypertension, since the business still reports no product revenue and continues to run losses. The biggest risk stays the same. Any delay, extra data requirements or weaker than expected reception for lorundrostat would affect both timelines and the ability to absorb growing operating costs.
The new AHA late breaking presentation stems from the Transform HTN open label extension, which aggregates long term efficacy and safety data for lorundrostat across multiple late stage studies. That operationally matters because Mineralys is trying to position CYP11B2 inhibition as a chronic, daily therapy, where durability and tolerability are scrutinised closely by regulators and prescribers.
This dataset also connects back to the firm’s broader lorundrostat program in chronic kidney disease and obstructive sleep apnea. Those proof of concept and Phase 2 efforts depend on a consistent safety profile, so long term hypertension data can influence how clinicians view potential future label expansion. Risk does not disappear, since competing aldosterone synthase inhibitors and Mineralys’ ongoing cash burn still frame the medium term execution challenge.
Mineralys Therapeutics' analyst narrative points to forecast revenue of US$467.2 million and expected earnings of US$16.6 million by 2029, compared with an earnings loss of US$349.6 million today. This implies an earnings swing of about US$366 million.
Uncover why Mineralys Therapeutics' fair value indicates an 82% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
Some of the lowest analysts focus less on the AHA spotlight and more on a tougher launch for Mineralys Therapeutics. They were only modeling about US$178.0 million of revenue by 2029 and assigning a P/E of roughly 140.7x on implied earnings of US$30.2 million. That is a far more cautious setup than the consensus. These views were formed before the new Transform HTN data, so treat them as starting points. Use them to stress test your own expectations and explore how sentiment could shift once the full long term results are understood.
Explore 3 other Mineralys Therapeutics fair value estimates, including one that suggests it could be worth just $48.50!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Mineralys Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Mineralys Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.
Looking For More Investment Ideas Beyond Mineralys Therapeutics?
Once you have a view on Mineralys Therapeutics, it can help to compare that thesis with other businesses that share some of the same financial traits. The Simply Wall St Screener is built for this kind of side by side work, so you can pressure test your thinking across different balance sheets, cash profiles and risk levels.
- If you want stability first and growth second, use the screener to pinpoint companies with stronger finances through our 31 resilient stocks with low risk scores.
- For investors who care most about paying less for quality, filter the market by valuation strength and fundamentals using the 30 high quality undervalued stocks.
- When the goal is to back under the radar stories with cleaner balance sheets, scan for stronger fundamentals across our 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com